Facts of Ertugliflozin
- Medicine Name: Ertugliflozin
- Approval Date: May 20 2013
- Company Name: Merck & Co., Inc. and Pfizer
- Available as (Form & Strength): Tablets: 5 mg and 10 mg.
What is Ertugliflozin?
Ertugliflozin is not authorised in the European Union. Studies in adults are currently on-going. This medicine is proposed in adults for the treatment of type 2 diabetes mellitus. Ertugliflozin works by blocking a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2). SGLT2 is a protein that absorbs glucose from the urine back into the bloodstream as the blood is filtered in the kidneys. By blocking the action of SGLT2 ertugliflozin causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.